Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Small Business Administration proposed rule

This article was originally published in The Gray Sheet

Executive Summary

Restructuring small business size standards, better measurement of employees for grant-eligibility and participation by venture capital are topics on which SBA seeks public comment, following a Dec. 3 proposed rule. The Medical Device Manufacturers Associations and the National Venture Capital Association have bristled at the restrictions on venture capital assistance, which could exclude from Small Business Innovation Research grants companies that are majority-owned by VC firms (1"The Gray Sheet" Dec. 22, 2003, p. 13). SBA's proposed rule notes that a majority of commenters endorsed an earlier proposal in March that sought to alter size requirements for SBIR grants. Comments on the December proposal are due Feb. 1. With the consolidated appropriations bill's passage into law Dec. 8, SBA was reauthorized for two years...

You may also be interested in...



SBIR Funding Ban on VC Firms Stifles Biotech Growth – Rep. Graves

Venture capital-backed firms should be allowed to compete for small business research grants, Rep. Sam Graves (R-Mo.) contended at the House Science/Environment, Technology & Standards Subcommittee hearing June 28

SBIR Eligibility For Venture Cap Encouraged By NVCA Data Gathering Effort

The National Venture Capital Association will attempt to quantify the total number of lives saved by VC-backed technologies in a report on the role of early-stage funding in medical device innovation

Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies

Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.

UsernamePublicRestriction

Register

MT021317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel